Koji Takeuchi

Koji Takeuchi

Auto-generated profile, based on publicly available information

Koji Takeuchi

Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan.

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KTKoji Takeuchi
Koji Takeuchi
This article reviews the pathogenic mechanism of non-steroidal anti-inflammatory drug (NSAID)-induced gastric damage, focusing on the relation between cyclooxygenase (COX) inhibition and various functional events. NSAIDs, such as indomethacin, at a dose that inhibits prostaglandin (PG) production, enhance gastric motility, resulting in an increase in mucosal permeability, neutrophil infiltration and oxyradical production, and eventually producing gastric lesions. These lesions are prevented by pretreatment with PGE₂ and antisecretory drugs, and also via an atropine-sensitive mechanism, not related to antisecretory action. Although neither rofecoxib (a selective COX-2 inhibitor) nor SC-560 (a selective COX-1 inhibitor) alone damages the stomach, the combined administration of these drugs provokes gastric lesions. SC-560, but not rofecoxib, decreases prostaglandin E₂ (PGE₂) production and causes gastric hypermotility and an increase in mucosal permeability. COX-2 mRNA is expressed in the stomach after administration of indomethacin and SC-560 but not rofecoxib. The up-regulation of indomethacin-induced COX-2 expression is prevented by atropine at a dose that inhibits gastric hypermotility. In addition, selective COX-2 inhibitors have deleterious influences on the stomach when COX-2 is overexpressed under various conditions, including adrenalectomy, arthritis, and Helicobacter pylori-infection. In summary, gastric hypermotility plays a primary role in the pathogenesis of NSAID-induced gastric damage, and the response, causally related with PG deficiency due to COX-1 inhibition, occurs prior to other pathogenic events such as increased mucosal permeability; and the ulcerogenic properties of NSAIDs require the inhibition of both COX-1 and COX-2, the inhibition of COX-1 upregulates COX-2 expression in association with gastric hypermotility, and PGs produced by COX-2 counteract the deleterious effect of COX-1 inhibition.

1 November 1999 in Gastroenterology
Verified
Journal Article
Closed access
KTKoji Takeuchi
Koji Takeuchi
HUHideki Ukawa
Hideki Ukawa
SKShinichi Kato
Shinichi Kato
OFOsamu Furukawa
Osamu Furukawa
HAHideo Araki
Hideo Araki
SNShuh Narumiya
Shuh Narumiya

1 January 2002 in Digestion
Verified
Journal Article
Closed access
PDF file
KTKoji Takeuchi
Koji Takeuchi
TMTohu Miyazawa
Tohu Miyazawa
ATAkiko Tanaka
Akiko Tanaka
SKShinichi Kato
Shinichi Kato
TKTomonori Kunikata
Tomonori Kunikata
Background/Aim: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin produce damage in the small intestine as a major adverse reaction. We examined the effect of various NSAIDs on intestinal motility and investigated the pathogenic importance of motility changes in the intestinal ulcerogenic response to indomethacin in rats. Methods: Animals without fasting were given various NSAIDs (indomethacin 10 mg/kg, diclofenac 40 mg/kg, flurbiprofen 20 mg/kg, naproxen 40 mg/kg) s.c., and in the case of indomethacin, the following parameters were examined in the small intestine 24 h later; the lesion score, the number of enterobacteria and myeloperoxidase (MPO) as well as inducible nitric oxide (iNOS) activity. Intestinal motility was monitored as intraluminal pressure recordings using a balloon under anesthesia. Results: All NSAIDs tested decreased mucosal PGE2 levels and produced hemorrhagic lesions in the small intestine, accompanied by intestinal hypermotility. As representative of NSAIDs, indomethacin also increased the extent of enterobacterial invasion and MPO as well as iNOS activity before the occurrence of intestinal damage, and the hypermotility response was observed earlier than the onset of any other event caused by this agent. The intestinal lesions induced by indomethacin were prevented by either supplementation with dmPGE2, inhibition of bacterial invasion with ampicillin or inhibition of iNOS activity with aminoguanidine, while the hypermotility response was prevented by dmPGE2 only. In addition, the observed effects of dmPGE2 were all mimicked by atropine when the intestinal hypermotility was suppressed by this agent. Conclusion: These results suggest the pathogenic importance of intestinal hypermotility in the intestinal ulcerogenic response to NSAIDs in rats and show that this event is critical for the occurrence of enterobacterial invasion under PG deficiency, followed by various inflammatory changes and damage in the mucosa. This study also suggests that the antispasmodic drug is protective against NSAID-induced intestinal lesions.

1 April 2010 in Clinica Chimica Acta
Verified
Journal Article
Closed access
KTKoji Takeuchi
Koji Takeuchi
ATAkiko Tanaka
Akiko Tanaka
SKShinichi Kato
Shinichi Kato
KAKikuko Amagase
Kikuko Amagase
HSHiroshi Satoh
Hiroshi Satoh

1 January 2010 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
KTKoji Takeuchi
Koji Takeuchi
SKShinichi Kato
Shinichi Kato
KAKikuko Amagase
Kikuko Amagase
Critical ReviewEndogenous prostaglandins (PGs) play an important role in modulating the mucosal integrity and various functions of the gastrointestinal tract, and E type PGs are most effective in these actions. PGE2 protected against acid-reflux esophagitis and prevented the development of gastric damage induced by ethanol or indomethacin, the effects mimicked by EP1 agonists and attenuated by an EP1 antagonist. Adaptive cytoprotection induced by mild irritants was also attenuated by the EP1 antagonist. On the other hand, the acid-induced duodenal damage was prevented by EP3/EP4 agonists and worsened by EP3/EP4 antagonists. Similarly, the protective effect of PGE2 on indomethacin-induced small intestinal damage or DSS-induced colitis was mimicked by EP3/EP4 agonists or EP4 agonists, respectively. The mechanisms underlying these actions of PGE2 are related to inhibition of stomach contraction (EP1), stimulation of duodenal HCO3− secretion (EP3/EP4), inhibition of small intestinal contraction (EP4), and stimulation of mucus secretion (EP3/EP4) or down-regulation of cytokine secretion in the colon (EP4), respectively. PGE2 also showed a healing-promoting effect on gastric ulcers and intestinal lesions through the activation of EP4 receptors, the effect associated with stimulation of angiogenesis via an increase in VEGF expression. These findings should aid the development of new strategies for treatment of gastrointestinal diseases.

16 January 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NNNobuyuki Negoro
Nobuyuki Negoro
SSShinobu Sasaki
Shinobu Sasaki
MIMasahiro Ito
Masahiro Ito
SKShuji Kitamura
Shuji Kitamura
YTYoshiyuki Tsujihata
Yoshiyuki Tsujihata
YMYu Momose
Yu Momose